Managers / Q4 2018 · view latest →
Matarin Capital Management, LLC
CIK 0001579668 · 420 LEXINGTON AVENUE, SUITE 2255, NEW YORK, NY, 10170 · 6466047640
Summary
Matarin Capital Management, LLC reported $1.24T in U.S.-listed holdings across 259 positions for Q4 2018.
Its largest position, EBS, represents 1.8% of the portfolio.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 91.3% · $1.13T
- Other · 4.3% · $53.7B
- REIT · 4.3% · $53.5B
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| EBSEmergent BioSolutions Inc. | NEW | +371.5K | 371.5K | +$22.0B | $22.0B |
| REGIEURRenewable Energy Group, Inc. | NEW | +749.9K | 749.9K | +$19.3B | $19.3B |
| USNAUSANA Health Sciences, Inc. | NEW | +142.7K | 142.7K | +$16.8B | $16.8B |
| GBCIGlacier Bancorp, Inc. | NEW | +405.8K | 405.8K | +$16.1B | $16.1B |
| BJRIBJ's Restaurants, Inc. | NEW | +311.1K | 311.1K | +$15.7B | $15.7B |
| FCNFTI Consulting, Inc. | NEW | +230.8K | 230.8K | +$15.4B | $15.4B |
| INVAInnoviva, Inc. | NEW | +863.2K | 863.2K | +$15.1B | $15.1B |
| ENTAEnanta Pharmaceuticals, Inc. | NEW | +209.9K | 209.9K | +$14.9B | $14.9B |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2018
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q4 2020 | $409M | 184 | Feb 3, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $501M | 190 | Aug 6, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $644M | 198 | Apr 27, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.0B | 235 | Feb 3, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $1.3B | 247 | Nov 5, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.4B | 256 | Aug 8, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | Under review | 262 | Apr 24, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $1.24T | 259 | Feb 6, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.